INSTRUCTIONS
for Use of the Veterinary Drug Letalbentum P
1. General Information

1.1 The veterinary drug Letalbentum P.

International nonproprietary name of the active pharmaceutical ingredient: Albendazole.

Dosage form: powder for oral administration.

1.2 The veterinary medicinal product Letalbent P (hereinafter referred to as the product) is a homogeneous light gray powder, a brownish tint is permissible.

1.3 The product contains 20% albendazole as the active ingredient and dextrose as an excipient.

1.4 The product is packaged in metallized polyethylene film bags of 100 g, 500 g, and 1000 g.

1.5 Store and transport the product in the manufacturer's original packaging in a place protected from direct sunlight at temperatures between 2°C and 25°C. Keep out of reach of children.

1.6 Shelf life: 3 years from the date of manufacture, provided storage and transportation conditions are met. Do not use after the expiration date. Dispose of unused product in accordance with legal regulations.

1.7 Dispensing conditions: available without a veterinary prescription.

2. Pharmacological Properties

2.1 Albendazole, the active component of the product, is a benzimidazole derivative effective against adult and immature nematodes of the genera *Haemonchus, Bunostomum, Oesophagostomum, Nematodirus, Ostertagia, Chabertia, Cooperia, Strongyloides, Ascaris, Trichostrongylus, Heterakis, Trichocephalus, Dictyocaulus, Protostrongylus, Muellerius, Metastrongylus*, cestodes of the genus *Moniezia*, and adult trematodes of the families *Fasciolidae* and *Dicrocoeliidae*.

2.2 The mechanism of action involves disrupting glucose transport and microtubule function, reducing fumarate reductase activity in helminths, impairing cell membrane permeability and neuromuscular innervation, which leads to paralysis and death of the parasites.

2.3 The product is not hepatotoxic. When administered orally, it is rapidly absorbed from the gastrointestinal tract, distributed to tissues and organs, and excreted primarily in the urine and bile; in lactating animals, also partially in milk.

2.4 The product is classified as moderately hazardous (hazard class III according to GOST 12.1.007-76) and does not have sensitizing effects.

3. Directions for Use

3.1 The drug is used for deworming cattle, sheep, goats, pigs, and poultry (broilers, turkeys, replacement pullets, parent stock) in the following cases: gastrointestinal nematodoses (haemonchosis, bunostomosis, esophagostomosis, nematodiriasis, ostertagiasis, habertiosis, cooperiosis, strongyloidosis, ascariasis, trichostrongyliasis, heterakidosis (heterakiasis), trichocephalosis), pulmonary nematodoses (dictyocaulosis, protostrongylosis, muelleriosis, metastrongylosis), cestodoses (monieziosis), trematodoses (fasciolosis, dicrocoeliosis).

3.2 Contraindication to the use of the drug is increased individual sensitivity to albendazole.

3.3 The drug is administered orally individually or in groups once with feed without prior fasting, to poultry – twice. Therapeutic treatments are carried out as indicated, preventive treatments quarterly in a therapeutic dose.

3.4 Cattle are given the drug individually at a dose of 3.75 g/100 kg of body weight for the treatment and prevention of monieziosis, pulmonary and gastrointestinal nematodoses. In cases of chronic fasciolosis, it is used at a dose of 5.0 g/100 kg of body weight.
Sheep are treated individually or in groups in the following doses: for monieziosis, pulmonary and gastrointestinal nematodoses – 2.5 g/100 kg of body weight; for chronic fasciolosis – 3.75 g/100 kg of body weight. For group administration, the weighed portion of the drug is calculated for a group of no more than 150 sheep, thoroughly mixed with compound feed (at the rate of 50–100 g of feed per animal). The mixture is placed in feeders ensuring free access.
Pigs are given the drug in the morning feeding in a group method with concentrated feed for the treatment and prevention of ascariasis and esophagostomosis. The drug is weighed for a group of no

more than 50 animals at the rate of 5.0 g/100 kg of body weight, mixed with half the feed ration and placed in feeders ensuring free access.
Poultry are treated against ascarids, heterakis, and mixed ascarid-heterakis invasions using a group method for two consecutive mornings with compound feed at a dose of 0.5 g/10 kg of body weight (10 mg of albendazole per 1 kg of body weight). The calculated dose is mixed with concentrated feed (according to the standard feed amount per animal in each age group).

3.5 Before mass treatments, each batch of the drug is tested on small groups of animals (5–15) of varying body condition and age. If no signs of toxicosis are observed in animals within 2 days after treatment, mass treatment may proceed.

3.6 The main symptoms of overdose are related to the drug's effect on hematopoiesis (leukopenia, granulocytopenia, agranulocytosis, thrombocytopenia) and liver function (increased activity of hepatic transaminases). The animal may exhibit motor discoordination and lethargy. In this case, the use of the drug is discontinued and symptomatic treatment is prescribed.

3.7 The drug is not allowed to be used in pregnant females, as well as in weakened, emaciated, or animals suffering from infectious diseases.

3.8 The drug must not be used in poultry whose eggs are intended for human consumption.

3.9 No side effects or complications are usually observed when the drug is used as directed. In cases of individual hypersensitivity to benzimidazole carbamate derivatives and allergic reactions, the use of the drug should be discontinued and symptomatic treatment prescribed.

3.10 Concurrent use of the drug with dexamethasone and cimetidine leads to an increase in the concentration of albendazole in the animal's blood.

3.11 Slaughter of pigs, cattle, and small ruminants for meat is permitted 20 days after drug administration, and poultry – 10 days after. In case of forced slaughter before the specified period, the meat may be used to feed carnivorous animals. Milk from dairy animals should not be used for food purposes for 14 days after deworming.

4. Precautionary Measures

4.1 When working with the drug, standard personal hygiene and safety precautions must be observed.

4.2 In case the components or the drug itself come into contact with the skin or mucous membranes, they must be rinsed off with water.

5. Claims Procedure

5.1 In case of complications following the use of the drug, its use must be discontinued, and the consumer should contact the state veterinary institution in the area where they are located. Veterinary specialists of this institution will assess whether all rules for the use of the drug, as outlined in the instructions, were followed. If a negative effect of the drug on the animal's body is confirmed, veterinary specialists will collect samples in the required quantity for laboratory testing and send them to the state institution "Belarusian State Veterinary Center" for verification of compliance with regulatory documents at the following address: Republic of Belarus, 220005, Minsk, 19A Krasnaya Street, Tel.: +375-17-290-42-75.

6. Manufacturer Information

6.1 Production Cooperative "Biogel".

Manufacturing site address: Republic of Belarus, 222685, Minsk Region, Stolbtsovsky District, Derevnoye Village.

Produced by order of Private Manufacturing and Trading Unitary Enterprise "Letyal", Republic of Belarus, 220075, Minsk, Inzhenernaya St., 1E.

This instruction was developed by employees of PC "Biogel" (L.E. Yanushevskaya) and PE "Letyal" (A.N. Bezborodkin).